glp-1 gilead Stock Gains. It's Trying to Get Into the Obesity Drug Game This gentle HER Speaker Series: GLP 1

GLP-1 medications are not recommended during pregnancy or breastfeeding, and some (like semaglutide) should be discontinued at least 2 months before a planned pregnancy

Our master nurse injectors understand this concern, so heres how we make your journey easier, more efficient, and patient friendly at InjectCo: *In a 68- and 72-week clinical trial studying Wegovy (2.4 mg) and Zepbound (15 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)

This method may not only restart progress but also reduce side effects

In our study, pretreatment HbA1C level was the dominant factor that affected GLP-1 M treatment outcome in the current analysis

[Google Scholar] [8].Davies M, Frch L, Jeppesen OK, et al

Why Blood Sugar May Not Be Very High In classic DKA: Insulin deficiency severe hyperglycemia In euglycemic DKA: Some insulin is still being administered Blood glucose may appear only mildly elevated But insulin is insufficient to prevent ketogenesis This can delay recognition because: Patients and clinicians may not suspect DKA with glucose under 250 mg/dL Symptoms may initially resemble dehydration or GI illness Additional Contributing Factors GLP-1 use in Type 1 diabetes may also increase DKA risk due to: Vomiting dehydration stress hormones ketone rise Intentional insulin reduction due to fear of hypoglycemia Reduced basal insulin during weight loss Increased glycemic variability from delayed gastric emptying Hypoglycemia and the Insulin Reduction Trap Another issue is the cycle that can develop: Appetite decreases Insulin dose is reduced Hypoglycemia occurs intermittently Insulin is reduced further Ketone production increases Over time, this can push the patient into metabolic instability